Full-Service Global CRO & Biologics Development CDMO
Phase I to Phase IV — Comprehensive CRO Capabilities
Scientific Proficiency at the Core of Trials
Global Reach. Local Expertise. Seamless Trial Execution."
Paving the Path to Regulatory Success
-
Full-Service Global CRO & Biologics CDMO
Offering decades of clinical research expertise, global compliance, and therapeutic experience to ensure your promising therapy isn’t delayed by risk or limited resources.
-
Phase I to Phase IV - Comprehensive CRO Capabilities
End-to-end solutions, from early-phase trials to post-marketing studies. Partner with us for comprehensive solutions that drive your success.
-
Scientific Proficiency at the Core of Trials
Deep therapeutic expertise across oncology, biosimilars, neuroscience, and 15+ domains, backed by experience of 290+ Clinical Trials.
-
Global Reach. Local Expertise. Seamless Trial Execution.
With operations across India, USA, Canada, UK, Spain, and Poland, Lambda brings local expertise and global reach to every clinical trial program.
-
Paving the Path to Regulatory Success
Navigating global regulatory frameworks with a proven compliance track record, enabling smooth submissions and consistent compliance for your clinical programs.
Capabilities
Comprehensive CRO capabilities spanning early to late-phase clinical development, supported by global operations, scientific expertise, and regulatory alignment.
Therapeutic Excellence
Advancing vital therapies across diverse therapeutic areas
Accelerating Biosimilar Development
Lambda holds a strong legacy in biosimilar development, covering a broad portfolio of molecules such as Adalimumab, Bevacizumab, Denosumab, Pertuzumab, Rituximab, Daratumumab, Trastuzumab, Trastuzumab Emtansine, Vedolizumab, Ranibizumab, Teriparatide, Aflibercept, Filgrastim, and Pegfilgrastim.
End-to-End Solutions
Full-service CRO Capabilities
Analytical Excellence
State-of-the-art lab with ELISA, ECLIA, IVD, Flow Cytometry and More
Accelerating Biosimilar Development
Lambda holds a strong legacy in biosimilar development, covering a broad portfolio of molecules such as Adalimumab, Bevacizumab, Denosumab, Pertuzumab, Rituximab, Daratumumab, Trastuzumab, Trastuzumab Emtansine, Vedolizumab, Ranibizumab, Aflibercept, Teriparatide, Filgrastim, and Pegfilgrastim.
End-to-End Solutions
Full-service offerings from Preclinical to Regulatory Support
Analytical Excellence
State-of-the-art lab with ELISA, ECLIA, IVD, Flow Cytometry & More
Why Lambda?
We bring together integrated capabilities and global operations to support biotech and pharmaceutical companies across clinical development and resource support needs.
A Global CRO with Operations across Continents
Full-Spectrum Clinical Research Services
Strong Credit Rating in the CRO Industry
Experienced Leadership team with Strong Industry Expertise
A Truly Global CRO with Multi-continental Presence
Comprehensive Clinical Research Services
Best Credit rating in CRO Industry
Strong Leadership with 20+ years of Experience
‘Regulatory & Compliance Excellence Award’ at the CPHI Pharma Awards 2023 for the exceptional work by Lambda in ‘Enhancing Compliance & Data Generation in Clinical Trials through Advanced Software Solutions and EDC Platform.’
‘Industry Partner of the Year’ Award
Global Generics & Biosimilar Awards 2023
Featured Research and Insights
Our Presence
We are aggressively expanding globally and are confident in our research initiatives, propelling us toward a trajectory of excellence.
Corporate Office – Ahmedabad
Lambda House, Plot No. 38,
Survey No. 388, Near Silver Oak University,
S.G. Highway, Gota, Ahmedabad - 382481,
Gujarat, India.
Representative Office
Poland (Warsaw)
Representative Office
UK (London)
Representative Office
Canada (Toronto)
Representative Office
US (Las Vegas)
Representative Office
Spain (Barcelona)
